More about the research at TIM

Denna sida på svenska

CAST was initially developed by Prof Olle Ringden and the administrative head of the department, Britt-Marie Svahn. 

Already today, many patients undergo treatments that modulate or harness the immune system with the ultimate aim to cure disease. The most well established procedure is hematopoietic stem cell transplantation in patients with leukemia and other malignancies. Such treatments are empirically developed and highly efficient in selected patients, but the actual immune processes are poorly understood and cannot be appreciated using available clinical measurements. Also, clinical complications after HSCT may evolve; these are immune mediated but cannot be predicted with current immune monitoring approaches.

In other diseases, such as chronic infections, the immune system may enter a stage of immune senescence or immune exhaustion associated with a decreased overall immune function, a pattern that may also be found in some healthy individuals associated with advanced age. Both of these immune processes appear to be independently regulated, yet we still lack a molecular and functional definition or understanding of how these processes evolve in different situation and during specific clinical situations. Global assessments of immune function can define subtle differences between patients and healthy individuals, or patients who respond as compared to those who do not respond to immune related therapies. TIM will facilitate better and earlier diagnosis of these conditions and work to offer better treatment modalities concerning prevention and treatment with a particular emphasis on cellular adaptive immune responses.

The clinical focus area includes novel immunotherapeutic approaches to diseases, treated at CAST, including treatment of (solid) tumors and infections with a particular focus on immune-response modifiers, novel immunotherapeutic compounds and cellular therapy. 

TIM works across different departmental structures, locally and internationally. 

  • Klas Kärre, MTC
  • Rolf Kiessling, CCK
  • Matthias Löhr, (ClinTec, Gastro)
  • Ralf Segersvärd (pancreas surgery )
  • Moustaffa Hassan (pre-clinical models, experimental hematology)
  • Magnus Westergren (gynecology)
  • Johan Permet (Innovationsplatsen)
  • Mathias Uhlen / Lars Engstrand, Science for Life Lab
  • Jacek Winiarski (Astrid Lindgren Childrens hospital, stem cell transplantation children) 

We aim to transfer very early on immunological readouts into a routine clinical setting with the emphasis of quality control with strong input from our clinical colleagues from Clinical Immunology to increase health care decisions. 

ImmunologyStem cells